ASCO GU 2026: vídeos e entrevistas
96 vídeos do ASCO GU 2026 publicados por ASCO Podcasts, Targeted Oncology, VJOncology, ecancer. Atualizado em 20/11/2026.
ASCO GU 2026: Updates in localised prostate cancerecancer · 15/05/2026 · 9:57 · apoio da indústria
ASCO GU 2026: Updates in metastatic bladder cancerecancer · 06/05/2026 · 11:02 · apoio da indústria
ASCO GU 2026: Updates in renal cancerecancer · 06/05/2026 · 11:35 · apoio da indústria
ASCO GU 2026: Updates in metstatic prostate cancerecancer · 06/05/2026 · 12:41 · apoio da indústria
mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunityecancer · 06/05/2026 · 6:36 · apoio da indústria
Biomarker-guided adjuvant therapy decisions in bladder cancerVJOncology · 16/03/2026 · 1:28 · apoio da indústria
External validation of multimodal artificial intelligence in the CHiP trialVJOncology · 16/03/2026 · 1:26 · apoio da indústria
Clinical and demographic disparities in prostate cancer surgery utilizationVJOncology · 16/03/2026 · 2:58 · apoio da indústria
ctDNA and utDNA biomarkers predict response in bladder cancerVJOncology · 16/03/2026 · 2:11 · apoio da indústria
HCRN GU 20-444: pembrolizumab and response-guided bladder-sparing in MIBCVJOncology · 16/03/2026 · 3:46 · apoio da indústria
CA IX–targeted PET imaging advances in clear cell renal carcinomaVJOncology · 16/03/2026 · 1:59 · apoio da indústria
Phase I/II study of CA IX imaging and therapy in renal cell carcinomaVJOncology · 16/03/2026 · 2:19 · apoio da indústria
De-escalation strategies to reduce ADT and ARPI burden in prostate cancerVJOncology · 16/03/2026 · 1:07 · apoio da indústria
OPTIMAS:a de-escalation trial in mHSPC achieving optimal PSA responseVJOncology · 16/03/2026 · 3:03 · apoio da indústria
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinomaVJOncology · 13/03/2026 · 1:51 · apoio da indústria
Reducing ADT use in low-PSA prostate cancer: insights from SAFE trialVJOncology · 10/03/2026 · 1:30 · apoio da indústria
SAVE: apalutamide versus ADT with salvage radiotherapy in prostate cancerVJOncology · 10/03/2026 · 1:05 · apoio da indústria
Future research trends in platelet polygenic risk scores in RCCVJOncology · 09/03/2026 · 1:18 · apoio da indústria
Germline platelet polygenic risk score predicts renal cell carcinoma survivalVJOncology · 09/03/2026 · 2:53 · apoio da indústria
Molecular subtyping in bladder cancer: luminal vs basal treatment insightsVJOncology · 09/03/2026 · 1:55 · apoio da indústria
Inclusion criteria of the EV-PRIME trial in muscle-invasive bladder cancerVJOncology · 09/03/2026 · 3:26 · apoio da indústria
Molecular subtypes of bladder cancer and therapeutic targetsVJOncology · 09/03/2026 · 6:36 · apoio da indústria
EV-PRIME: enfortumab vedotin, pembrolizumab and radiotherapy in MIBCVJOncology · 09/03/2026 · 3:34 · apoio da indústria
KIM-1 biomarker research in renal cancer: current limitations and potentialVJOncology · 06/03/2026 · 1:52 · apoio da indústria
ctDNA in bladder cancer: interpreting results and clinical limitationsVJOncology · 06/03/2026 · 1:56 · apoio da indústria
Will ctDNA becoming a routine postoperative risk stratification tool in MIBC?VJOncology · 06/03/2026 · 4:01 · apoio da indústria
Patient-reported outcomes in adjuvant renal cell carcinoma therapyVJOncology · 06/03/2026 · 1:01 · apoio da indústria
KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trialVJOncology · 06/03/2026 · 2:08 · apoio da indústria
Top updates from ASCO GU 2026: latest trials in prostate, kidney, and bladder cancerVJOncology · 06/03/2026 · 17:51 · apoio da indústria
Highlights From the 2026 ASCO GU Cancers SymposiumASCO Podcasts · 05/03/2026 · 20:10
Lifestyle, diet and microbiome research in urinary cancer outcomesVJOncology · 05/03/2026 · 2:27 · apoio da indústria
CYTOSHRINK: SBRT with ipilimumab and nivolumab in treatment-naïve mRCCVJOncology · 05/03/2026 · 2:21 · apoio da indústria
De-escalating therapy after major neoadjuvant response in MIBCVJOncology · 05/03/2026 · 1:07 · apoio da indústria
Biomarker development and validation in prostate cancer researchVJOncology · 05/03/2026 · 1:16 · apoio da indústria
Immune checkpoint therapy hyper-progression in renal medullary carcinomaVJOncology · 05/03/2026 · 2:20 · apoio da indústria
Cure potential and treatment goals in metastatic solid tumor oncologyVJOncology · 05/03/2026 · 1:20 · apoio da indústria
Cretostimogene and durable immune response in bladder cancerVJOncology · 05/03/2026 · 1:27 · apoio da indústria
Phase Ib trial of pasritamig, a bispecific BiTE, and docetaxel in mCRPCVJOncology · 05/03/2026 · 2:30 · apoio da indústria
PRESERVE-006: Phase I trial of gotistobart and 177Lu-PSMA-617 in mCRPCVJOncology · 05/03/2026 · 2:00 · apoio da indústria
ULTRA-HERO: radiotherapy & relugolix for intermediate risk prostate cancerVJOncology · 05/03/2026 · 1:06 · apoio da indústria
MONSTAR-SCREEN-3: ultra-sensitive ctDNA detection in urothelial cancerVJOncology · 04/03/2026 · 1:27 · apoio da indústria
Identifying patients with prostate cancer who will benefit from radium-223VJOncology · 04/03/2026 · 1:25 · apoio da indústria
Interpreting PEACE-3 trial data and combination strategies in prostate cancerVJOncology · 04/03/2026 · 2:04 · apoio da indústria
Real-world post–177Lu-PSMA-617 treatment patterns & outcomes in mCRPCVJOncology · 04/03/2026 · 1:08 · apoio da indústria
CLIMATE: miR-371 as an MRD marker in stage 1 testicular cancerVJOncology · 04/03/2026 · 1:48 · apoio da indústria
Systemic therapy advances and personalized bladder cancer treatmentVJOncology · 04/03/2026 · 1:44 · apoio da indústria
Supporting clinician well-being to improve patient care outcomesVJOncology · 04/03/2026 · 1:10 · apoio da indústria
Digital interventions and global delivery of prostate cancer support programsVJOncology · 04/03/2026 · 1:25 · apoio da indústria
Cardiometabolic risks of novel hormonal therapies in prostate cancerVJOncology · 04/03/2026 · 1:34 · apoio da indústria
Cardiovascular risk factors with hormonal therapies in prostate cancerVJOncology · 04/03/2026 · 2:41 · apoio da indústria
Evaluating the future of miRNA and ctDNA as testicular cancer biomarkersVJOncology · 04/03/2026 · 1:36 · apoio da indústria
Using perioperative ctDNA for treatment selection in bladder cancerVJOncology · 04/03/2026 · 1:20 · apoio da indústria
Advancing VEGF–HIF2 strategies in clear cell renal cell carcinomaVJOncology · 04/03/2026 · 1:02 · apoio da indústria
Biomarkers and imaging in bladder-sparing MIBC in the Indi-Blade trialVJOncology · 04/03/2026 · 2:31 · apoio da indústria
Indi-Blade: induction ipilimumab, nivolumab, and chemoradiotherapy in MIBCVJOncology · 04/03/2026 · 2:03 · apoio da indústria
Why PSMA Scans Might Be Deceiving in Cancer Treatment #GU26 #prostatecancerTargeted Oncology · 03/03/2026 · 1:16 · apoio da indústria
Prostate cancer at ASCO GU 2026: PEACE-3, BRCAAway, and T-cell engagersVJOncology · 03/03/2026 · 1:24 · apoio da indústria
Kidney cancer highlights at ASCO GU 2026: LITESPARK-011 & LITESPARK-022VJOncology · 03/03/2026 · 1:47 · apoio da indústria
Selecting patients with high-risk NMIBC for BCG-immunotherapy strategiesVJOncology · 03/03/2026 · 1:28 · apoio da indústria
TulmiSTAR-01: tulmimetostat with luxdegalutamide in mCRPCVJOncology · 03/03/2026 · 1:16 · apoio da indústria